B
Bull
Bull · 25%YMAB
$6.16
Precio del escenario
$8.610
+0.020 (+0.23%)Al cierre
Loading chart…
- High
- 8.610
- Open
- 8.590
- VWAP
- 8.60
- Vol
- 760.67K
- Mkt Cap
- 541.07M
- Low
- 8.590
- Amount
- 6.54M
- EV/EBITDA, TTM
- -8.59
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Analyst Ratings (2)
-7.32% downside
Buy
2 Buy
0 Hold
0 Sell
Current: 8.61
Mínimo
3.00
Promedio
7.98
Máximo
8.60
H.C. Wainwright
Neutral
$11
2025-08-06
H.C. Wainwright
2025-08-06
Precio objetivo
$11
Neutral
Wedbush
Neutral
—
2025-08-05
Wedbush
2025-08-05
Precio objetivo
—
Neutral
Cantor Fitzgerald
Neutral
$19
2025-08-05
Cantor Fitzgerald
2025-08-05
Precio objetivo
$19
Neutral
Clear Street
Hold
$17
2025-08-05
Clear Street
2025-08-05
Precio objetivo
$17
Hold
Truist
Hold
$14
2025-08-05
Truist
2025-08-05
Precio objetivo
$14
Hold
Métricas de valoración
The current forward P/E ratio for Y-mAbs Therapeutics Inc (YMAB) is -6.07, compared to its 5-year average forward P/E of -11.09.
Alphio AI Price Scenarios for YMAB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
7.008-26GlobenewswireSHAREHOLDER INQUIRY: Halper Sadeh LLC Probes VRNT, DAY, WOW, YMAB for Shareholder Interests
7.008-26GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Verint Systems Inc. (Nasdaq – VRNT), Dayforce, Inc. (NYSE – DAY), WideOpenWest, Inc. (NYSE – WOW), and Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
7.008-21GlobenewswireSHAREHOLDER INQUIRY: Halper Sadeh LLC Probes DAY, WOW, YMAB, STAA for Shareholder Interests
7.008-21GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Dayforce, Inc. (NYSE- DAY), WideOpenWest, Inc. (NYSE - WOW), STAAR Surgical Company (Nasdaq – STAA), and Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
7.008-20GlobenewswireSHAREHOLDER INQUIRY: Halper Sadeh LLC Probes VBTX, TASK, YMAB for Shareholder Interests
YMAB FAQ — answered by Alphio AI
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
2 analysts cover YMAB: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.98.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.